Investor Relations

Castlight Health Announces First Quarter 2021 Results
04/29/2021
Company Demonstrates Sequential Increase in ARR and Increases 2021 Outlook

SAN FRANCISCO, April 29, 2021 /PRNewswire/ -- Castlight Health, Inc. (NYSE:CSLT), a leading health navigation platform provider, today announced results for its first quarter ended March 31, 2021.

"We executed well in the first quarter and made meaningful progress against each of our three priorities for 2021 while delivering strong financial results, including sequential ARR growth and our fourth straight quarter of non-GAAP profitability," said Maeve O'Meara, chief executive officer of Castlight Health. "We were pleased with our pipeline generation activity in the quarter, reported our lowest churn quarter since 2016, and expanded a key health plan partnership. We demonstrated our commitment and ability to innovate in the category of next generation navigation with the launch of our market-leading vaccine navigation solution. Finally, we expanded and extended our work with Boston Children's Hospital to support the nation's ongoing COVID-19 vaccination effort. Our progress in the first quarter allows us to increase our financial guidance for 2021."

Financial performance for the three months ended March 31, 2021 compared to the three months ended March 31, 2020 includes:

  • Total revenue of $35.1 million, compared to $39.0 million
  • GAAP gross margin of 63.6%, compared to 62.9%
  • Non-GAAP gross margin of 66.8%, compared to 65.1%
  • GAAP operating loss of $3.1 million, compared to $56.6 million
  • Non-GAAP operating income of $1.2 million, compared to an operating loss of $2.2 million
  • GAAP net loss per basic and diluted share of $0.02, compared to a net loss per basic and diluted share of $0.38
  • Non-GAAP net income per basic and diluted share of $0.01, compared to a net loss per basic and diluted share of $0.01
  • Cash provided by operations of $7.6 million, compared to cash used in operations of $14.4 million

Total cash was $56.5 million as of March 31, 2021.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

Business Outlook

For the full year 2021, the Company is increasing its outlook and now expects:

  • Revenue in the range of $135 million to $140 million
  • Non-GAAP operating income between income of $1 million and a loss of $4 million
  • Non-GAAP net income per share between income of $0.01 and a loss of $0.03, based on approximately 160 million to 161 million shares

For the second quarter of 2021, the Company now expects:

  • Revenue in the range of $33 million to $35 million

Quarterly Conference Call

Castlight Health senior management will host a conference call to discuss its first quarter 2021 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company's Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367. The conference ID number for the live call and replay is 2847469.

About Castlight Health

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system and live happier, healthier, more productive lives. As a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical and benefits experts to help members easily connect and engage with the right programs and care, at the right time. Castlight partners with Fortune 500 companies and health plans to transform employee and member benefits into one comprehensive health and wellbeing experience to deliver better health outcomes and maximize returns on healthcare investments.

For more information visit www.castlighthealth.com.  Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures

To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude goodwill impairment, stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, capitalization and amortization of internal-use software, and lease exit and related charges.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company's historical financial performance. However, these non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

The non-GAAP measures we provide may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the Company's financial information in its entirety and not rely on a single financial measure.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2021 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software, are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Words such as "anticipates," "expects," "intends," "plans," "projects," "believes," "seeks," "estimates," "can," "may," "will," "would" and similar expressions identify such forward-looking statements. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. The forward-looking statements about Castlight Health's expectations, plans, intentions, and strategies include, but are not limited to, statements regarding certain 2021 financial projections, and our expectations for our future business and financial performance. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health's documents filed with or furnished to the Securities and Exchange Commission, including the risks set forth in our annual report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on February 24, 2021, and our quarterly reports on Form 10-Q, including the quarterly report for the three months ended March 31, 2021, when filed with the SEC. All forward-looking statements in this press release are expressly qualified in their entirety by these cautionary statements and are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements, except as required by law. 

Copyright 2021 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(unaudited)



As of


March 31, 2021


December 31, 2020

Assets




Current assets:




Cash and cash equivalents

$

56,501



$

49,242


Accounts receivable and other, net

25,035



31,740


Prepaid expenses and other current assets

6,772



3,800


Total current assets

88,308



84,782


Property and equipment, net

4,966



5,321


Restricted cash, non-current

1,144



1,144


Deferred commissions

8,190



9,556


Deferred professional service costs

4,205



4,462


Intangible assets, net

6,872



7,930


Goodwill

41,485



41,485


Operating lease right-of-use assets, net

9,131



10,238


Other assets

1,838



1,855


Total assets

$

166,139



$

166,773


Liabilities and stockholders' equity




Current liabilities:




Accounts payable

$

4,383



$

5,145


Accrued expenses and other current liabilities

7,057



7,898


Accrued compensation

4,755



8,633


Deferred revenue

13,135



6,848


Operating lease liabilities

5,939



5,789


Total current liabilities

35,269



34,313


Deferred revenue, non-current

122



663


Operating lease liabilities, non-current

5,907



7,446


Other liabilities, non-current

480



485


Total liabilities

41,778



42,907


Stockholders' equity

124,361



123,866


Total liabilities and stockholders' equity

$

166,139



$

166,773


 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)


Three Months Ended March 31,


2021


2020

Revenue:




Subscription

$

32,110



$

38,383


Professional services and other

2,949



662


Total revenue, net

35,059



39,045


Cost of revenue:




Cost of subscription(1)

8,099



10,232


Cost of professional services and other(1)

4,657



4,241


Total cost of revenue

12,756



14,473


Gross profit

22,303



24,572


Operating expenses:




Sales and marketing(1)

6,913



10,472


Research and development(1)

12,113



13,822


General and administrative(1)

6,366



6,576


Goodwill impairment



50,300


Total operating expenses

25,392



81,170


Operating loss

(3,089)



(56,598)


Other income, net

93



263


Net loss

$

(2,996)



$

(56,335)


Net loss per share, basic and diluted

$

(0.02)



$

(0.38)


Weighted-average shares used to compute basic and diluted net loss per share

156,781



148,872








(1)   Includes stock-based compensation expense as follows:

 


Three Months Ended March 31,


2021


2020

Cost of revenue:




Cost of subscription

$

257



$

169


Cost of professional services and other

236



116


Sales and marketing

350



672


Research and development

1,069



1,163


General and administrative

1,195



1,066


 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)


Three Months Ended March 31,


2021


2020

Operating activities:




Net loss

$

(2,996)



$

(56,335)


Adjustments to reconcile net loss to net cash provided by (used in) operating activities:




Depreciation and amortization

1,623



1,535


Goodwill impairment



50,300


Stock-based compensation

3,107



3,186


Amortization of deferred commissions

1,340



2,383


Amortization of deferred professional service costs

580



925


Non-cash operating lease expense

1,107



1,400


Accretion and amortization of marketable securities



2


Changes in operating assets and liabilities:




Accounts receivable and other, net

6,705



(6,676)


Deferred commissions

26



(318)


Deferred professional service costs

(300)



(416)


Prepaid expenses and other assets

(2,955)



(494)


Accounts payable

(759)



(7,462)


Operating lease liabilities

(1,389)



(1,516)


Accrued expenses and other liabilities

(382)



19


Deferred revenue

5,746



3,573


Accrued compensation

(3,878)



(4,465)


Net cash provided by (used in) operating activities

7,575



(14,359)


Investing activities:




Purchase of property and equipment

(212)



(1,264)


Purchase of marketable securities



(1,989)


Maturities of marketable securities



12,400


Net cash (used in) provided by investing activities

(212)



9,147


Financing activities:




Proceeds from exercise of stock options

128



155


Proceeds from ESPP offering

233



186


Principal payments on long-term debt

(465)



(465)


Net cash used in financing activities

(104)



(124)






Net increase (decrease) in cash, cash equivalents and restricted cash

7,259



(5,336)


Cash, cash equivalents and restricted cash at beginning of period

50,386



44,342


Cash, cash equivalents and restricted cash at end of period

$

57,645



$

39,006






Reconciliation of cash, cash equivalents and restricted cash:




Cash and cash equivalents

$

56,501



$

37,681


Restricted cash included in Prepaid expenses and other current assets



181


Restricted cash, non-current

1,144



1,144


Total cash, cash equivalents and restricted cash

$

57,645



$

39,006



 


Three Months Ended


March 31, 2021


December 31, 2020


March 31, 2020

Gross profit:






GAAP gross profit subscription

$

24,011



$

26,487



$

28,151


Stock-based compensation

257



215



169


Amortization of internal-use software

79



80



26


Amortization of intangibles

530



530



530


Non-GAAP gross profit subscription

$

24,877



$

27,312



$

28,876


GAAP gross margin subscription

74.8

%


77.0

%


73.3

%

Non-GAAP gross margin subscription

77.5

%


79.4

%


75.2

%







GAAP gross loss professional services

$

(1,708)



$

(2,322)



$

(3,579)


Stock-based compensation

236



219



116


Non-GAAP gross loss professional services

$

(1,472)



$

(2,103)



$

(3,463)


GAAP gross margin professional services

(58)

%


(87)

%


(541)

%

Non-GAAP gross margin professional services

(50)

%


(79)

%


(523)

%







GAAP gross profit

$

22,303



$

24,165



$

24,572


Impact of non-GAAP adjustments

1,102



1,044



841


Non-GAAP gross profit

$

23,405



$

25,209



$

25,413


GAAP gross margin

63.6

%


65.2

%


62.9

%

Non-GAAP gross margin

66.8

%


68.0

%


65.1

%







Operating expense:






GAAP sales and marketing

$

6,913



$

7,713



$

10,472


Stock-based compensation

(350)



(326)



(672)


Amortization of intangibles

(528)



(528)



(528)


Non-GAAP sales and marketing

$

6,035



$

6,859



$

9,272








GAAP research and development

$

12,113



$

11,418



$

13,822


Stock-based compensation

(1,069)



(1,041)



(1,163)


Certain legal expenses





191


Capitalization of internally developed software





21


Non-GAAP research and development

$

11,044



$

10,377



$

12,871








GAAP general and administrative

$

6,366



$

6,405



$

6,576


Stock-based compensation

(1,195)



(1,085)



(1,066)


Amortization of intangibles





(17)


Non-GAAP general and administrative

$

5,171



$

5,320



$

5,493








GAAP goodwill impairment

$



$



$

50,300


Goodwill impairment





(50,300)


Non-GAAP goodwill impairment

$



$



$








GAAP operating expense

$

25,392



$

25,536



$

81,170


Impact of non-GAAP adjustments

(3,142)



(2,980)



(53,534)


Non-GAAP operating expense

$

22,250



$

22,556



$

27,636








Operating loss:






GAAP operating loss

$

(3,089)



$

(1,371)



$

(56,598)


Impact of non-GAAP adjustments

4,244



4,024



54,375


Non-GAAP operating income (loss)

$

1,155



$

2,653



$

(2,223)








Net loss and net loss per share:






GAAP net loss

$

(2,996)



$

(1,197)



$

(56,335)


Total pre-tax impact of non-GAAP adjustments

4,244



4,024



54,375


Non-GAAP net income (loss)

$

1,248



$

2,827



$

(1,960)


GAAP net loss per share, basic and diluted

$

(0.02)



$

(0.01)



$

(0.38)


Non-GAAP net income (loss) per share, basic and diluted

$

0.01



$

0.02



$

(0.01)


Shares used in basic and diluted net loss per share computation

156,781



154,739



148,872



 

Castlight Media Contact:
Caroline Kawashima
press@castlighthealth.com  
415-246-0313

Castlight Investor Contact:
ir@castlighthealth.com  
443-213-0500

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/castlight-health-announces-first-quarter-2021-results-301280618.html

SOURCE Castlight Health, Inc.

Contact Investor Relations

Email Alerts